During early expiration the sudden airway pressure release causes the nitric oxide captured in the delivery line to empty into the Ypiece and subsequently to be washed out by the expiratory flow. Both effects reduce the amount of nitric oxide delivered to the lungs. These losses are more pronounced in patients with low lung compliance receiving low doses of nitric oxide.
As most of the aforementioned characteristics are specific to the chosen site of nitric oxide administration, we suggest that nitric oxide should be added to the breathing gas as close to the inspiratory outlet of the ventilator as possible. In this way, the volume of the entire inspiratory limb, including the humidifier, can be used as a mixing chamber. This single measure reduces the requirement both for the high dynamic range and the fast response of the MFC. It guarantees a uniform nitric oxide concentration during the entire inspiration and avoids inaccuracies in nitric oxide measurement arising from incomplete gas mixing as is to be expected when nitric oxide is delivered close to the gas sampling location. However, one must observe that this modification increases the contact time for oxygen and nitric oxide and thus might contribute to a higher conversion of nitric oxide into nitrogen dioxide, but nitrogen dioxide should always be monitored whenever nitric oxide is administered to a patient [4] .
In general, any system, when used for administration of a potent drug, must remain safe and must not harm the patient in the event of even a single fault. As Young pointed out, in the case of a power loss, nitric oxide delivery from the MFC is promptly shut down. However, a nitric oxide "responding" patient may experience a dangerous increase in pulmonary artery pressure or a deterioration in oxygenation caused by sudden withdrawal of the drug, or both [4] . On the other hand, if the mass flow unit fails, nitric oxide delivery cannot be controlled and might exceed the upper range of the MFC. This event might be accompanied by exceedingly high nitric oxide concentrations. In our opinion, the patient must be protected irrespective of any of these conditions by an independent safety valve. Young correctly stated that for clinical use a nitric oxide monitor would be mandatory. At present, however, there is no nitric oxide monitor available which would respond fast enough to measure the nitric oxide concentration on a breath-to-breath basis ("fast" chemiluminescence nitric oxide monitors sample at least 500 ml min" 1 , thus affecting the inspiratory flow pattern and any inspiratory hold phase). Even if such a monitor is available, it is highly questionable if in Young's method, mixing has occurred just a few centimetres downstream to the nitric oxide inlet so that a valid inspiratory nitric oxide concentration could be measured.
Nevertheless, in summary, we appreciate Young's mass flow controlled nitric oxide delivery device as an essential step in setting a first clinical "standard" for accurate nitric oxide concentration delivery. To our knowledge, devices with a certification by an independent test house are not yet available in the market, and so the anaesthetist must be fully aware of his responsibilities when administering a potentially toxic drug such as nitric oxide (the efficacy of which is only now being investigated in a multicentre phase II study). Therefore, anaesthetists are strongly advised to observe all respective safety guidelines when using a custom-tailored nitric oxide delivery device. Sir,-Drs Gilly and Baum have clearly highlighted some of the problems using mass flow controllers for nitric oxide delivery in a critical care setting. The prototype device I constructed could undoubtedly be improved using a faster mass flow controller with a wider dynamic range, or possibly by carefully adjusting the damping on the mass flow controller feed-back loop. Intermittent compression and release of nitric oxide mixtures from the delivery line was not a problem I had considered when constructing the original device. In addition to the suggested solution, other approaches would be to place a check valve in the delivery line close to the point at which it enters the expiratory limb, or to mount the mass flow controller remotely from the rest of the device, close to the circuit.
Abrupt cessation of nitric oxide treatment can cause a serious rebound increase in pulmonary vascular resistance. This may occur if power is lost to the device. Our current solution is to have a second nitric oxide system available for such an emergency but a fixed-flow bypass valve that opens automatically on power loss may be more appropriate. This gives a variable inspired concentration of nitric oxide depending on the minute ventilation, but if the bypass flow is chosen appropriately, a safe level could be delivered which would prevent abrupt cessation of treatment. An additional point to be borne in mind is that if the patient is removed from the ventilator circuit and the lungs ventilated by another means, for instance a manual ventilating circuit, some method has to be available to deliver the nitric oxide to the second circuit.
The device I described is an undoubted improvement on the continuous flow systems we have used up until now. It does, however, represent the first step in the development of an automated system, and not the final solution. Sir,-Thank you for the opportunity to reply to Dr Jayasuriya's letter. We agree that the use of the term "critical incident" poses problems. We headed our list of terms "notable or untoward events in patient care" because a critical incident is so difficult to define. Thus an event can be labelled as being "critical" depending on the view of the anaesthetist concerned.
